Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring Common EGFR Mutations Treated With Afatinib

NCT04909073 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT04909073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04909073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring Common EGFR Mutations Treated With Afatinib
Lead sponsor
National University Hospital, Singapore
Phase
Observational
Overall status
Unknown status
Start date
October 25, 2022
Completion date
December 31, 2025
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epidermal growth factor receptor mutation, non-small cell lung cancer